Status:
COMPLETED
Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Approximately 30% of patients with rheumatoid arthritis have an inadequate response to anti-TNF (primarily or loss of response), leaving two alternatives: rotation to a second anti-TNF or change of bi...
Eligibility Criteria
Inclusion
- Active and erosive rheumatoid arthritis with a DAS28 equal or greater than 3.2
- Inadequate response to a 1st anti-TNF
- Stable or no treatment with any DMARDs, or oral corticosteroids (\< or = to 10 mg/day of prednisone equivalent)during the preceding month
Exclusion
- Counter-indication to other anti-TNF, abatacept, rituximab or tocilizumab
- Pregnancy
- Age \< 18 years
- Impossibility to give informed consent
- Impossibility to be followed for 12 months
Key Trial Info
Start Date :
December 23 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 12 2013
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT01000441
Start Date
December 23 2009
End Date
August 12 2013
Last Update
August 9 2021
Active Locations (44)
Enter a location and click search to find clinical trials sorted by distance.
1
Polyclinique de Picardie
Amiens, France
2
Centre Hospitalier de Belfort-Montbéliard
Belfort, France
3
CHU de Besançon - Hôpital Jean Minjoz
Besançon, France
4
Hôpital Jean Verdier
Bondy, France